Introduction
============

As a type of inflammation in the pancreas, pancreatitis is frequently due to excessive alcohol consumption and gallstones ([@b1-mmr-14-06-5451]--[@b3-mmr-14-06-5451]). Patients with pancreatitis often suffer from upper abdominal pain, nausea and vomiting ([@b4-mmr-14-06-5451],[@b5-mmr-14-06-5451]) and may develop complications, including diabetes, infection and bleeding ([@b6-mmr-14-06-5451]--[@b8-mmr-14-06-5451]). Globally, the pancreatitis-associated deaths in 2013 were 123,000, up from 83,000 deaths in 1990 ([@b9-mmr-14-06-5451]). Therefore, it is urgent to investigate the underlying molecular mechanisms that lead to pancreatitis.

MicroRNAs (miRNAs) are 22-nucleotide single-stranded and small non-coding RNAs that regulate post-transcriptional expression of genes in eukaryotes and function in diverse biological processes ([@b10-mmr-14-06-5451],[@b11-mmr-14-06-5451]). miRNAs, which are more stable compared with mRNAs, which is essential for the robustness of diagnostic assays ([@b12-mmr-14-06-5451]). In comparison with normal pancreatic tissue, several miRNAs, including *miR-99*, *miR-100*, *miR-125a*, *miR-199a-1*, *miR-199a-2* have been previously identified to be overexpressed in pancreatic cancer and in chronic pancreatitis ([@b13-mmr-14-06-5451]). In pancreatic cancer cells, tumor-suppressing miR-96 may act as a novel therapeutic marker for the treatment of pancreatic cancer via targeting the Kirsten rat sarcoma viral oncogene homolog oncogene ([@b14-mmr-14-06-5451]). *CD40* targeted by *miR-224* and *miR-486* may be of importance to the progression of pancreatic ductal adenocarcinomas (PDACs) and may have diagnostic and therapeutic potential in PDACs ([@b15-mmr-14-06-5451]). Cell division cycle 25B, which may contribute to proliferation of PDACs, has been identified as a novel target of *miR-148a* ([@b16-mmr-14-06-5451]). A previous study indicated that *miR-10a* was upregulated in various pancreatic cancers and correlated with the invasive potential of pancreatic cancer cells by inhibiting homeobox A1 ([@b17-mmr-14-06-5451]). In the present study, differentially expressed miRNAs (DE-miRNAs) in pancreatitis were screened using miRNA expression profile of GSE24279. The genes targeted by DE-miRNAs were predicted and their potential functions were analyzed by functional and pathway enrichment analysis. Subsequently, pancreatitis-associated genes were identified from the target genes and the regulatory networks of pancreatitis-associated genes and miRNAs that targeted them were constructed.

Materials and methods
=====================

### Microarray data

The miRNA expression profile of GSE24279 was downloaded from the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)), which was based on the platform of GPL10944 febit human miRBase version 11. A collective of 27 pancreatitis and 22 normal control samples were selected from GSE24279 to investigate the mechanisms of pancreatitis.

### Screening for DE-miRNAs

Using the vsn package ([@b18-mmr-14-06-5451]) in Bioconductor, version 2.7, microarray data was preprocessed using robust estimation of variance-stabilizing and calibrating transformations to obtain an expression matrix of miRNAs. The limma package ([@b19-mmr-14-06-5451]) in Bioconductor was used to screen the DE-miRNAs between pancreatitis samples and control samples. The P-values of miRNAs were calculated using the t-test function in the limma package and adjusted for multiple comparisons using the Benjamini & Hochberg method ([@b20-mmr-14-06-5451]). The adjusted P\<0.05 and \|log~2~ fold-change (FC)\|≥0.58 (corresponded to 1.5-fold) were used as the cut-off criteria.

### Analysis of genes targeted by DE-miRNAs

The genes targeted by DE-miRNAs were predicted using the miRecords (<http://c1.accurascience.com/miRecords/>) ([@b21-mmr-14-06-5451]) and miRWalk ([www.umm.uni-heidelberg.de/apps/zmf/mirwalk/](www.umm.uni-heidelberg.de/apps/zmf/mirwalk/)) ([@b22-mmr-14-06-5451]) databases. A DE-miRNA-gene pair was required to appear in at least one database as a filtering condition.

### Functional and pathway enrichment analysis

Gene Ontology (GO) analysis was used to predict the potential functions of the gene products, including molecular function (MF), biological process (BP) and cellular component (CC) categories ([@b23-mmr-14-06-5451]). The Kyoto Encyclopedia of Genes and Genomes (KEGG), which consists of the PATHWAY, GENES and LIGAND databases was used to identify molecular functions ([@b24-mmr-14-06-5451]). Using the Database for Annotation, Visualization and Integrated Discovery (DAVID) ([@b25-mmr-14-06-5451]) online tool, GO and KEGG pathway enrichment analyses were performed for the genes targeted by the DE-miRNAs. Parameters of EASE ≤0.05 and count ≥2 were used as the thresholds. The remaining parameters were set to defaults.

### Regulatory network construction

There may be pancreatitis-associated genes among the target genes of DE-miRNAs, and it is suggested that miRNAs that targeted them may have been involved in pancreatitis progression. Therefore, the Comparative Toxicogenomics Database (CTD; [ctd.mdibl.org](ctd.mdibl.org)) ([@b26-mmr-14-06-5451]) was used to identify pancreatitis-associated genes. Next, the regulatory network of pancreatitis-associated genes and miRNAs that targeted them were visualized using Cytoscape software, version 2.8 ([www.cytoscape.org](www.cytoscape.org)) ([@b27-mmr-14-06-5451]).

Results
=======

### Analysis of DE-miRNAs and their target genes

There were 14 upregulated and 39 downregulated miRNAs screened in pancreatitis samples compared with the control samples. There were more downregulated miRNAs compared with upregulated miRNAs. The heat map of DE-miRNAs is presented in [Fig. 1](#f1-mmr-14-06-5451){ref-type="fig"}. A total 424 DE-miRNA-gene pairs were identified in the miRecords and miRWalk databases and 290 target genes of DE-miRNAs were obtained.

### Functional and pathway enrichment analysis

The functions of target genes were predicted using the DAVID online tool, and the GO and KEGG pathway enrichment analyses. The enriched GO functions for the target genes are presented in [Table I](#tI-mmr-14-06-5451){ref-type="table"}, including the positive regulation of macromolecule metabolic process (P=1.20×10^−32^) in the BP category, nuclear lumen (P=1.25×10^−14^) in the CC category and sequence-specific DNA binding (P=2.73×10^−18^) in the MF category. The enriched KEGG pathways for target genes included pathways in cancer (P=5.32×10^−16^), focal adhesion (P=1.70×10^−7^) and pancreatic cancer (P=3.08×10^−5^; [Table II](#tII-mmr-14-06-5451){ref-type="table"}). Cyclin D1 (*CCND1*), v-akt murine thymoma viral oncogene homolog 2 (*AKT2*), cyclin-dependent kinase 6 (*CDK6*) and SMAD family member 2 (*SMAD2*) were specifically involved in the pancreatic cancer pathway.

### Regulatory network analysis

The CTD database revealed that a total of 279 genes out of the 290 target genes were associated with pancreatitis and were targeted by 37 miRNAs. The regulatory network of pancreatitis-associated genes and the miRNAs that targeted them is presented in [Fig. 2](#f2-mmr-14-06-5451){ref-type="fig"}. It is of note that *hsa-miR-15a* targeted 56 genes, including *CCND1*, *hsa-miR-16* targeted 63 genes including *CCND1*, *hsa-miR-155* targeted 20 genes, including *CCND1* and *SMAD2*, *hsa-miR-375* targeted 44 genes, including *AKT2* and *CDK6* and *hsa-miR-429* targeted 59 genes, including *CCND1* Additionally, *hsa-miR-16* targeted the highest number of genes in the regulatory network ([Fig. 3](#f3-mmr-14-06-5451){ref-type="fig"}).

Discussion
==========

In the present study, 14 upregulated and 39 downregulated miRNAs were identified in the screened pancreatitis samples compared with the control samples. A total 424 DE-miRNA-gene pairs were identified in the miRecords and miRWalk databases and 290 target genes of DE-miRNAs were obtained. It is of note that *CCND1*, *AKT2*, *CDK6* and *SMAD2* were involved in the pancreatic cancer pathway. Among the target genes, 279 genes were pancreatitis-associated genes, which were targeted by 37 miRNAs in the regulatory network.

*miR-155*, which has abnormal expression in the early stage of pancreatic cancer, may be used as a biomarker for intraductal papillary mucinous neoplasms ([@b28-mmr-14-06-5451]). *miR-155*, *miR-203*, *miR-210* and *miR-222* have an oncogenic function in the development and progression of pancreatic cancer by targeting several genes; therefore, it is possible that the tumorigenesis and tumor progression of PDAC was influenced by a complex signaling network ([@b29-mmr-14-06-5451]). *miR-15a* directly targeted multiple pancreatic cancer-associated genes and its downregulation may aid the proliferation of pancreatic cancer cells, indicating that it may be used as a novel therapeutic target for the disease ([@b30-mmr-14-06-5451]). Pathway enrichment revealed that *CCND1* was also involved in pancreatic cancer progression. Previous studies determined that *CCND1*, which is frequently co-overexpressed with *CCND3* ([@b31-mmr-14-06-5451]), integrated extracellular mitogenic signaling and impacted tumor cell migration in PDAC ([@b32-mmr-14-06-5451]). Upregulated *CCND1* promoted chemoresistance of pancreatic cancer cells by facilitating cell proliferation and suppression of drug-induced apoptosis ([@b33-mmr-14-06-5451]). As a component of the E-cadherin-catenin cell adhesion complex, β-catenin may also contribute to the tumorigenesis of pancreatic cancer primarily by transactivation of *CCND1* ([@b34-mmr-14-06-5451]). In the regulatory network, *hsa-miR-15a*, *hsa-miR-16*, *hsa-miR-155* and *hsa-miR-429* targeted more genes than other miRNAs, and *CCND1* was a common target gene. This indicated that *hsa-miR-15a*, *hsa-miR-16*, *hsa-miR-155* and *hsa-miR-429* may be important for the regulation of pancreatitis via *CCND1*.

In PDAC, SMAD protein expression levels in stromal fibroblasts and in epithelial tumor cells was correlated with both stromal features and a shorter postsurgical overall survival ([@b35-mmr-14-06-5451]). Overexpression of the embryonic protein Nodal may lead to a metastatic phenotype in pancreatic carcinoma cells by the SMAD2/3 pathway. Therefore, Nodal may be a potential target for treatment of pancreatic cancer ([@b36-mmr-14-06-5451]). A previous study determined that the expression levels of transforming growth factor β1 and *SMAD2* in pancreatic adenocarcinoma were higher when compared with the normal control pancreatic parenchyma and their expression correlated with the tumor stage ([@b37-mmr-14-06-5451]). In the present study, *SMAD2* was enriched in the pathway of pancreatic cancer. In addition, *SMAD2* was targeted by *hsa-miR-155* in the regulatory network. Therefore, *hsa-miR-155* may also function in pancreatitis by mediating *SMAD2*.

A previous study indicated that the anticancer agent benzyl isothiocyanate may inhibit the proliferation of pancreatic cancer cells via regulation of the expression levels of *miR-375* and *miR-221* ([@b38-mmr-14-06-5451]). Elevated *miR-375* affected proliferation, apoptosis and cell cycle distribution of pancreatic cancer cells; therefore, *miR-375* may contribute to novel treatments for pancreatic cancer ([@b39-mmr-14-06-5451]). Pathway enrichment also indicated that *AKT2* and *CDK6* were involved in pancreatic cancer progression. *AKT2* is frequently activated by upstream perturbations of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which may contribute to the pathogenesis of highly aggressive pancreatic cancer ([@b40-mmr-14-06-5451]). It has been determined that suppression of extracellular signal-regulated kinase and PI3K/AKT pathways activate forkhead members of the class O (*FOXO*) transcription factor and strengthen transcriptional activity of sulforaphane-induced *FOXO*, resulting in cell cycle arrest and cell apoptosis in pancreatic cancer ([@b41-mmr-14-06-5451]). Downregulation of *CDK6* and *p16* may be involved in cell cycle progression and transformation of endocrine tumors, including pancreatic endocrine neoplasms ([@b42-mmr-14-06-5451]). Overexpression of *CDK4* and *CDK6* may result in a stronger response in patients with pancreatic neuroendocrine tumors treated with CDK4/6 inhibitors ([@b43-mmr-14-06-5451]). In the regulatory network constructed in the present study, *hsa-miR-375* targeted 44 genes, including *AKT2* and *CDK6*, suggesting that *hsa-miR-155* targeting *AKT2* and *CDK6* may also contribute to pancreatitis.

In conclusion, the present study performed a comprehensive bioinformatics analysis, and identified 14 upregulated and 39 downregulated miRNAs in pancreatitis samples compared with control samples. Additionally, *hsa-miR-15a*, *hsa-miR-16* and *hsa-miR-429* were determined to target *CCND1*, *hsa-miR-155* targeted *CCND1* and *SMAD2* and *hsa-miR-375* targeted *AKT2* and *CDK6*; therefore, these miRNAs may contribute to the pathogenesis of pancreatitis and be potential therapeutic targets. However, these predictions require further experimental validation in future studies.

![Heat map of differentially expressed miRNAs. Red indicates upregulated miRNAs. Green indicates downregulated miRNAs. miRNA, microRNA.](MMR-14-06-5451-g00){#f1-mmr-14-06-5451}

![Regulatory network of pancreatitis-associated genes and their target miRNAs. Circle nodes indicate pancreatitis-associated genes. Square nodes represent differentially expressed miRNAs. Red nodes stand for upregulated miRNAs and green nodes for down-regulated miRNAs. miRNA, microRNA.](MMR-14-06-5451-g01){#f2-mmr-14-06-5451}

![The number of pancreatitis-associated genes targeted by each differentially expressed miRNA. miRNA, microRNA.](MMR-14-06-5451-g02){#f3-mmr-14-06-5451}

###### 

The enriched functions for target genes of differentially expressed microRNAs.

  Category   Term         Description                                                 Gene number   Gene symbol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          P-value
  ---------- ------------ ----------------------------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------
  BP         GO:0010604   Positive regulation of macromolecule metabolic process      80            *MYOD1, PPARA, HNF1A, PDGFB, BTRC, MITF, PPARG, SNCA, SPI1, FOXO1, TLR4, PDX1, ZEB1, FOXO3, GLI2, GLI3, IL10, CTNNB1, TGFB2, CCNE1, GATA6, FOXF1, HMOX1, IFNG, YAP1, MKL1, MYC, IHH, AKT2, IRS2, EGR2, RARG, ESR1, RB1, PPARGC1A, HMGA1, GTF2H1, ACVR2A, CCND1, EP300, HNF4A, CCND3, CCND2, JUN, FOXC2, ZFPM2, CLOCK, CSF1, SOX2, SOX9, SRF, WT1, IGF1R, IL17A, HAND1, AGT, BCL2, POU3F1, RUNX1, DNMT3B, RUNX2, CEBPB, MAFB, NR4A2, CD276, SMAD3, SMAD2, HDAC4, NOTCH1, SP1, PLK1, ETS1, NOTCH4, FOXE1, DNMT1, JAK2, TNK2, MTOR, BMP7, KLF4*         1.20×10^−32^
             GO:0009891   Positive regulation of biosynthetic process                 67            *PPARA, MYOD1, HNF1A, PDGFB, PPARG, MITF, SPI1, FOXO1, TLR4, PDX1, ZEB1, FOXO3, GLI2, GLI3, IL10, CTNNB1, TGFB2, CCNE1, GATA6, FOXF1, HMOX1, IFNG, YAP1, MKL1, MYC, AKT2, IHH, IRS2, EGR2, RARG, RB1, PPARGC1A, HMGA1, GTF2H1, EP300, HNF4A, JUN, FOXC2, ZFPM2, CLOCK, SOX2, SOX9, SRF, WT1, IGF1R, IL17A, HAND1, AGT, PRKAA1, RUNX1, RUNX2, CEBPB, MAFB, NR4A2, CD276, SMAD3, SMAD2, HDAC4, NOTCH1, SP1, ETS1, NOTCH4, FOXE1, JAK2, MTOR, BMP7, KLF4*                                                                                               9.62×10^−28^
             GO:0010557   Positive regulation of macromolecule biosynthetic process   64            *PPARA, MYOD1, HNF1A, PDGFB, PPARG, MITF, SPI1, FOXO1, TLR4, PDX1, FOXO3, ZEB1, GLI2, GLI3, IL10, CTNNB1, TGFB2, CCNE1, GATA6, FOXF1, HMOX1, IFNG, YAP1, MKL1, MYC, AKT2, IHH, IRS2, EGR2, RARG, RB1, PPARGC1A, HMGA1, GTF2H1, EP300, HNF4A, JUN, FOXC2, ZFPM2, CLOCK, SOX2, SOX9, SRF, WT1, IGF1R, IL17A, HAND1, RUNX1, RUNX2, CEBPB, MAFB, NR4A2, CD276, SMAD3, SMAD2, HDAC4, NOTCH1, SP1, ETS1, NOTCH4, FOXE1, MTOR, BMP7, KLF4*                                                                                                                  8.77×10^−27^
             GO:0031328   Positive regulation of cellular biosynthetic process        65            *PPARA, MYOD1, HNF1A, PDGFB, PPARG, MITF, SPI1, FOXO1, TLR4, PDX1, ZEB1, FOXO3, GLI2, GLI3, IL10, CTNNB1, CCNE1, GATA6, FOXF1, HMOX1, IFNG, YAP1, MKL1, MYC, AKT2, IHH, IRS2, EGR2, RARG, RB1, PPARGC1A, HMGA1, GTF2H1, EP300, HNF4A, JUN, FOXC2, ZFPM2, CLOCK, SOX2, SOX9, SRF, WT1, IGF1R, IL17A, HAND1, AGT, RUNX1, RUNX2, CEBPB, MAFB, NR4A2, CD276, SMAD3, SMAD2, HDAC4, NOTCH1, SP1, ETS1, NOTCH4, FOXE1, JAK2, MTOR, BMP7, KLF4*                                                                                                              1.79×10^−26^
             GO:0010628   Positive regulation of gene expression                      60            *PPARA, MYOD1, HNF1A, PPARG, MITF, SPI1, FOXO1, PDX1, FOXO3, ZEB1, GLI2, GLI3, IL10, CTNNB1, CCNE1, GATA6, FOXF1, IFNG, YAP1, MKL1, MYC, IHH, RARG, EGR2, ESR1, RB1, HMGA1, PPARGC1A, GTF2H1, EP300, HNF4A, JUN, FOXC2, ZFPM2, CLOCK, CSF1, SOX2, SOX9, SRF, WT1, IL17A, HAND1, POU3F1, RUNX1, RUNX2, DNMT3B, CEBPB, MAFB, NR4A2, SMAD3, SMAD2, HDAC4, NOTCH1, SP1, ETS1, NOTCH4, FOXE1, DNMT1, BMP7, KLF4*                                                                                                                                          3.06×10^−26^
  CC         GO:0031981   Nuclear lumen                                               69            *BACH1, MYOD1, RNASEL, NBN, HNF1A, CDC14B, EZH2, FOXO1, ZEB1, GLI3, IQGAP1, CTNNB1, PNN, PRIM1, CCNE1, GATA6, FOXF1, HMOX1, YAP1, MYB, MYC, TWIST2, ZBTB20, RARG, UBE2I, RB1, PPARGC1A, HMGA1, GTF2H1, CCND1, EP300, HNF4A, CFL2, JUN, MATR3, CLOCK, ME1, MTDH, MCL1, HOXA11, SOX2, SOX9, SRF, WT1, HAND1, NPAT, POU3F1, WIPF1, DNMT3B, RUNX2, DNMT3A, CEBPB, TBX2, MAFB, PHB, NLK, SMAD3, SMAD2, ATM, POLD3, RPS6KA5, HDAC4, SNAI3, SP1, PLK1, TDG, JAK2, RERE, KLF4*                                                                               1.25×10^−14^
             GO:0005667   Transcription factor complex                                26            *MYOD1, HNF1A, HOXA11, SOX2, ZEB1, CTNNB1, GATA6, FOXF1, POU3F1, YAP1, RUNX2, TWIST2, RARG, TBX2, MAFB, SMAD3, SMAD2, RB1, HMGA1, GTF2H1, SNAI3, EP300, HNF4A, JUN, KLF4, CLOCK*                                                                                                                                                                                                                                                                                                                                                                     3.85×10^−14^
             GO:0005654   Nucleoplasm                                                 49            *MYOD1, NBN, HNF1A, EZH2, FOXO1, ZEB1, GLI3, CTNNB1, PNN, PRIM1, CCNE1, GATA6, FOXF1, YAP1, MYC, TWIST2, RARG, UBE2I, RB1, HMGA1, PPARGC1A, GTF2H1, CCND1, EP300, HNF4A, JUN, CLOCK, MCL1, HOXA11, SOX2, WT1, HAND1, NPAT, POU3F1, RUNX2, TBX2, MAFB, PHB, SMAD3, SMAD2, ATM, RPS6KA5, POLD3, HDAC4, SNAI3, PLK1, TDG, KLF4, RERE*                                                                                                                                                                                                                   1.44×10^−12^
             GO:0031974   Membrane-enclosed lumen                                     75            *BACH1, MYOD1, RNASEL, NBN, HNF1A, PDGFB, CDC14B, EZH2, FOXO1, ZEB1, GLI3, IQGAP1, CTNNB1, TGFB2, PNN, PRIM1, CCNE1, GATA6, FOXF1, HMOX1, YAP1, MYB, MYC, TWIST2, ZBTB20, RARG, UBE2I, RB1, PPARGC1A, HMGA1, GTF2H1, TIMM8A, CCND1, EP300, C1QBP, HNF4A, CFL2, JUN, MATR3, CLOCK, ME1, MTDH, MCL1, HOXA11, SOX2, SOX9, SRF, WT1, HAND1, NPAT, WIPF1, POU3F1, DNMT3B, RUNX2, DNMT3A, CEBPB, TBX2, MAFB, PHB, NLK, SMAD3, SMAD2, SPARC, ATM, POLD3, RPS6KA5, HDAC4, HSP90B1, SNAI3, SP1, PLK1, TDG, JAK2, RERE, KLF4*                                  2.47×10^−12^
             GO:0043233   Organelle lumen                                             74            *BACH1, MYOD1, RNASEL, NBN, HNF1A, PDGFB, CDC14B, EZH2, FOXO1, ZEB1, GLI3, IQGAP1, CTNNB1, TGFB2, PNN, PRIM1, CCNE1, GATA6, FOXF1, HMOX1, YAP1, MYB, MYC, TWIST2, ZBTB20, RARG, UBE2I, RB1, PPARGC1A, HMGA1, GTF2H1, CCND1, EP300, C1QBP, HNF4A, CFL2, JUN, MATR3, CLOCK, ME1, MTDH, MCL1, HOXA11, SOX2, SOX9, SRF, WT1, HAND1, NPAT, WIPF1, POU3F1, DNMT3B, RUNX2, DNMT3A, CEBPB, TBX2, MAFB, PHB, NLK, SMAD3, SMAD2, SPARC, ATM, POLD3, RPS6KA5, HDAC4, HSP90B1, SNAI3, SP1, PLK1, TDG, JAK2, RERE, KLF4*                                          2.78×10^−12^
  MF         GO:0043565   Sequence-specific DNA binding                               51            *BACH1, PPARA, MYOD1, HNF1A, PPARG, MITF, SPI1, FOXO1, FOXO3, ZEB1, PDX1, GLI2, GLI3, CTNNB1, GATA6, FOXF1, MYC, RARG, SOX13, ESR1, HMGA1, HNF4A, JUN, FOXC2, HOXA11, SOX2, SOX9, SRF, WT1, HAND1, HOXA5, POU3F1, DNMT3B, CREBL2, FOXL1, CEBPB, TBX2, MAFB, MSH2, NR4A2, SMAD3, SMAD2, HDAC4, NOTCH1, NR1I2, SP1, MEOX2, ETS1, FOXE1, KLF4, RERE*                                                                                                                                                                                                    2.73×10^−18^
             GO:0016563   Transcription activator activity                            41            *MYOD1, PPARA, HNF1A, MITF, PPARG, FOXO1, PDX1, FOXO3, ZEB1, SOX9, GLI2, WT1, CTNNB1, CCNE1, HAND1, GATA6, FOXF1, BCL2, NPAT, YAP1, POU3F1, MKL1, MYB, RUNX1, RUNX2, CEBPB, PHB, NR4A2, SMAD3, SMAD2, RB1, HMGA1, PPARGC1A, HDAC4, NOTCH1, NR1I2, EP300, SP1, HNF4A, FOXC2, KLF4*                                                                                                                                                                                                                                                                    3.06×10^−17^
             GO:0030528   Transcription regulator activity                            79            *BACH1, PPARA, MYOD1, HNF1A, ZNFX1, EZH2, PPARG, MITF, SPI1, FOXO1, PDX1, ZEB1, FOXO3, GLI2, GLI3, CTNNB1, CCNE1, GATA6, FOXF1, YAP1, MYB, MKL1, MYC, TWIST2, TWIST1, EGR2, RARG, SOX13, MECP2, ESR1, UBE2I, RB1, PPARGC1A, HMGA1, GTF2H1, MYCN, EP300, HNF4A, JUN, MAP3K10, FOXC2, ZFPM2, CLOCK, HOXA11, SOX2, SOX9, SRF, WT1, HAND1, HOXA5, BCL2, NPAT, POU3F1, RUNX1, DNMT3B, RUNX2, CREBL2, PLAG1, CEBPB, FOXL1, TBX2, MAFB, JARID2, PHB, NR4A2, SMAD3, SMAD2, HDAC4, NOTCH1, SNAI3, NR1I2, SP1, MEOX2, DMTF1, ETS1, FOXE1, FABP4, RERE, KLF4*   3.63×10^−16^
             GO:0003700   Transcription factor activity                               61            *BACH1, PPARA, MYOD1, HNF1A, ZNFX1, PPARG, MITF, SPI1, FOXO1, PDX1, FOXO3, ZEB1, GLI2, GLI3, CTNNB1, GATA6, FOXF1, MYC, TWIST2, RARG, EGR2, SOX13, ESR1, RB1, HMGA1, MYCN, EP300, HNF4A, JUN, FOXC2, CLOCK, HOXA11, SOX2, SOX9, SRF, WT1, HAND1, HOXA5, NPAT, POU3F1, RUNX1, RUNX2, CREBL2, PLAG1, CEBPB, FOXL1, TBX2, MAFB, NR4A2, SMAD3, SMAD2, SNAI3, NOTCH1, NR1I2, SP1, MEOX2, ETS1, DMTF1, FOXE1, RERE, KLF4*                                                                                                                                  9.84×10^−16^
             GO:0008134   Transcription factor binding                                35            *MYOD1, NBN, YWHAZ, MTDH, PPARG, ZEB1, SRF, CTNNB1, CCNE1, HAND1, GATA6, BCL2, NPAT, YAP1, MKL1, RUNX1, DNMT3B, RARG, MAFB, NLK, MECP2, SMAD3, SMAD2, RB1, HMGA1, PPARGC1A, HDAC4, EP300, NR1I2, HNF4A, ETS1, JUN, MAP3K10, DNMT1, ZFPM2*                                                                                                                                                                                                                                                                                                            5.43×10^−10^

BP, biological process; CC, cellular component; MF, molecular function.

###### 

The enriched pathways for target genes of differentially expressed microRNAs.

  Term       Description                              Gene number   Gene symbol                                                                                                                                                                                                                                                                    P-value
  ---------- ---------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------
  hsa05200   Pathways in cancer                       41            *FGFR3, PDGFB, MITF, PPARG, SPI1, FOXO1, GLI2, GLI3, TGFB2, CTNNB1, WNT2, CCNE1, CDC42, IGF1R, KRAS, BCL2, RHOA, RUNX1, MYC, AKT2, COL4A2, COL4A1, MSH2, MET, TGFBR2, SMAD3, RAF1, CDK6, FADD, SMAD2, RB1, SMO, NRAS, CCND1, HSP90B1, CDKN1B, EP300, ETS1, JUN, MTOR, LAMC1*   5.32×10^−16^
  hsa04510   Focal adhesion                           22            *COL4A2, COL4A1, PDGFB, COL3A1, MET, RAF1, COL2A1, CTNNB1, KDR, CDC42, IGF1R, CCND1, PDPK1, CCND3, CCND2, JUN, BCL2, COL1A2, RHOA, COL1A1, LAMC1, AKT2*                                                                                                                        1.70×10^−7^
  hsa04060   Cytokine-cytokine receptor interaction   18            *CCL1, PDGFB, CSF1, MET, TGFBR2, IL13, CCL27, IL10, TGFB2, KDR, AMH, ACVR2A, IL17A, IL23A, INHBE, INHBC, IFNG, BMP7*                                                                                                                                                           0.001139
  hsa05215   Prostate cancer                          17            *PDGFB, FOXO1, RAF1, RB1, CTNNB1, CCNE1, NRAS, IGF1R, HSP90B1, CCND1, PDPK1, EP300, CDKN1B, KRAS, BCL2, MTOR, AKT2*                                                                                                                                                            2.48×10^−9^
  hsa04010   MAPK signaling pathway                   17            *FGFR3, PDGFB, NLK, TGFBR2, MAP2K4, RAF1, HSPA1A, SRF, TAB2, TGFB2, RPS6KA5, CDC42, NRAS, KRAS, JUN, MYC, AKT2*                                                                                                                                                                0.003593
  hsa04110   Cell cycle                               16            *YWHAZ, CDC14B, SMAD3, CDK6, SMAD2, RB1, ATM, TGFB2, CCNE1, CCND1, EP300, CDKN1B, CCND3, CCND2, PLK1, MYC*                                                                                                                                                                     1.99×10^−6^
  hsa04520   Adherens junction                        15            *CDC42, IGF1R, EP300, WASF3, NLK, TGFBR2, MET, RHOA, SMAD3, SMAD2, SNAI2*,... *YES1, SNAI1, IQGAP1, CTNNB1*                                                                                                                                                                    2.25×10^−8^
  hsa05210   Colorectal cancer                        15            *MSH2, MET, TGFBR2, SMAD3, RAF1, SMAD2, TGFB2, CTNNB1, IGF1R, CCND1, KRAS, BCL2, JUN, MYC, AKT2*                                                                                                                                                                               7.17×10^−8^
  hsa04310   Wnt signaling pathway                    15            *WNT2, CSNK1A1, CCND1, EP300, SFRP1, CCND3, CCND2, JUN, NLK, BTRC, RHOA, SMAD3, SMAD2, MYC, CTNNB1*                                                                                                                                                                            8.61×10^−5^
  hsa05212   Pancreatic cancer                        11            *CDC42, CCND1, KRAS, TGFBR2, SMAD3, RAF1, CDK6, SMAD2, RB1, TGFB2, AKT2*                                                                                                                                                                                                       3.08×10^−5^

MAPK, mitogen-activated protein kinase.
